Skip to main content

Pipeline

Dati, scienza e tecnologia che diventano terapia

Silthera sviluppa programmi focalizzati su malattie genetiche rare e ultra-rare, con particolare attenzione alle mutazioni autosomiche dominanti, dove il bisogno clinico è elevato e la precisione progettuale è un fattore decisivo.

Silthera develops programs focused on rare and ultra-rare genetic diseases, with a specific emphasis on autosomal dominant mutations, where clinical need is high and design precision is a decisive factor

Fasi di sviluppo dei profarmaci

Silthera-001

Disease Area: Visceral myopathy type 1
Target: Mutated gene associated with smooth muscle dysfunction

Discovery

Preclinical Research

Regulatory Preclinical

Clinical

Status: Regulatory Preclinical
Technology: siRNA


Silthera-002

Disease Area: Visceral myopathy type 2
Target: Mutated gene associated with smooth muscle dysfunction

Discovery

Preclinical Research

Regulatory Preclinical

Clinical

Status: Preclinical Research
Technology: siRNA


Silthera-003

Disease Area: Osteogenesis imperfecta
Target: Genetic bone disorders

Discovery

Preclinical Research

Regulatory Preclinical

Clinical

Status: Preclinical Research
Technology: siRNA


Silthera-004

Disease Area: Undisclosed

Discovery

Preclinical Research

Regulatory Preclinical

Clinical

Status: Discovery
Technology: siRNA

Scopri le opportunità di partnership

Contattaci

© Silthera è un marchio di Loto Biotech Platform s.r.l.
Spin off dell’Università degli Studi dell’Aquila

Privacy Preference Center